The DOI matches its Crossref record; 14 of the 15 references it cites were found in a registry or an index.
The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013
Open accessAbstract
Importance: It is important to understand the magnitude and distribution of the economic burden of prescription opioid overdose, abuse, and dependence to inform clinical practice, research, and other decision makers. Decision makers choosing approaches to address this epidemic need cost information to evaluate the cost effectiveness of their choices. Objective: To estimate the economic burden of prescription opioid overdose, abuse, and dependence from a societal perspective. Design, Setting, and Participants: Incidence of fatal prescription opioid overdose from the National Vital Statistics System, prevalence of abuse and dependence from the National Survey of Drug Use and Health. Fatal data are for the US population, nonfatal data are a nationally representative sample of the US civilian noninstitutionalized population ages 12 and older. Cost data are from various sources including health care claims data from the Truven Health MarketScan Research Databases, and cost of fatal cases from the WISQARS (Web-based Injury Statistics Query and Reporting System) cost module. Criminal justice costs were derived from the Justice Expenditure and Employment Extracts published by the Department of Justice. Estimates of lost productivity were based on a previously published study. Exposure: Calendar year 2013. Main Outcomes and Measures: Monetized burden of fatal overdose and abuse and dependence of prescription opioids. Results: The total economic burden is estimated to be $78.5 billion. Over one third of this amount is due to increased health care and substance abuse treatment costs ($28.9 billion). Approximately one quarter of the cost is borne by the public sector in health care, substance abuse treatment, and criminal justice costs. Conclusions and Relevance: These estimates can assist decision makers in understanding the magnitude of adverse health outcomes associated with prescription opioid use such as overdose, abuse, and dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“many of these domains are featured in existing studies of the economic burden of SUDs”
From Monetary conversion factors for economic evaluations of substance use disorders (2017) · cites this paper as Florence et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“This is a change from previously published estimates, where a large share of costs was attributable to opioid use disorder (Birnbaum et al., 2011; Florence et al., 2016; Rice et al., 2014).”
From The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017 (2021) · cites this paper as Florence et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“Matching controlled for basic demographic variables, health status was matched based on the Charlson comorbidity index and health care costs prior to use disorder diagnosis, and regression models controlled for skewness in the expenditure data.”
From The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017 (2021) · cites this paper as Florence et al., 2016
The cited source says what the claim attributes to it.
In the citing paper
“The original source study used a matched case-control design to estimate the impact of opioid use disorder diagnoses on health care spending.”
From The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017 (2021) · cites this paper as Florence et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
Paulozzi, L. J., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011) · PubMed · Cited by 1,350
Pharmaceutical Overdose Deaths, United States, 2010
Jones, C. M., Mack, K. A., & Paulozzi, L. J. (2013) · JAMA · doi:10.1001/jama.2013.272 · Cited by 678
Societal costs of prescription opioid abuse, dependence, and misuse in the United States
Birnbaum, H. G., White, A. G., Schiller, M., Waldman, T., Cleveland, J. M., & Roland, C. L. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01075.x · Cited by 644
Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008.
(2011) · PubMed · Cited by 640
CDC grand rounds: prescription drug overdoses - a U.S. epidemic.
(2012) · PubMed · Cited by 502
CDC grand rounds: prescription drug overdoses - a U.S. epidemic.
(2012) · PubMed · Cited by 494
Economic Costs of Nonmedical Use of Prescription Opioids
Hansen, R. N., Oster, G., Edelsberg, J., WOODY, G. E., & Sullivan, S. D. (2010) · Clinical Journal of Pain · doi:10.1097/ajp.0b013e3181ff04ca · Cited by 183
Economic Burden of Prescription Opioid Misuse and Abuse
Strassels, S. A. (2009) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2009.15.7.556 · Cited by 148
Estimated Costs of Prescription Opioid Analgesic Abuse in the United States in 2001
Birnbaum, H. G., White, A. G., Reynolds, J. L., Greenberg, P. E., Zhang, M., Vallow, S., Schein, J. R., & Katz, N. P. (2006) · Clinical Journal of Pain · doi:10.1097/01.ajp.0000210915.80417.cf · Cited by 139
Ballesteros, M. F., Webb, K. B., & McClure, R. (2017) · Journal of Safety Research · doi:10.1016/j.jsr.2017.01.001 · Cited by 126
Cited by
Sorted by citations
Ferreira, M. L., de Luca, K. E., Haile, L. M., Steinmetz, J. D., Culbreth, G. T., Cross, M., Kopec, J. A., Ferreira, P. H., Blyth, F., Buchbinder, R., et al. (2023) · The Lancet Rheumatology · doi:10.1016/s2665-9913(23)00098-x · Cited by 2,122
CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022
Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7103a1 · Cited by 1,886
Vital signs: changes in opioid prescribing in the United States, 2006-2015.
Guy, G. P., Zhang, K., Bohm, M. K., Losby, J., Lewis, B., Young, R., Murphy, L. B., & Dowell, D. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6626a4 · Cited by 1,117
Nelson, G., Bakkum-Gamez, J., Kalogera, E., Glaser, G., Altman, A., Meyer, L., Taylor, J. S., Iniesta, M., Lasala, J., Mena, G., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000356 · Cited by 678
Hah, J. M., Bateman, B. T., Ratliff, J., Curtin, C., & Sun, E. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002458 · Cited by 728
Metadata
- Authors
- Florence, C. S., Zhou, C., Luo, F., & Xu, L.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Venue
- Medical Care
- Published
- 2016-10
- Volume
- 54
- Issue
- 10
- Pages
- 901-906
- ISSN
- 0025-7079 (ISSN-L)
- PMC
- PMC5975355
- OpenAlex
- W2519105412
- Cited by
- 1,152
- References
- 15
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 51 · 2023: 79 · 2022: 125 · 2021: 195 · 2020: 265 · 2019: 185 · 2018: 128 · 2017: 45 · 2016: 5
- FWCI
- 119.97
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Medical Care (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (CC999999)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- prescription opioid overdose, opioid abuse, opioid use disorder, economic burden, social costs, health care costs, criminal justice costs, productivity loss, fatal overdose, opioid epidemic
- MeSH terms
- Absenteeism, Prescription Drug Overuse, Criminal Law, Female, Humans, Male, Opioid-Related Disorders, United States, Health Care Costs, Cost of Illness, Prescription Drug Misuse
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
